Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), announced the significant results from their further analysis of its Optina™ trial on DME
This article: 643 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE